Soft Anticholinergic Esters Treat Sialorrhea, Bodor Labs
Summary
Bodor Laboratories, Inc. has filed patent application US20260108491A1 (Application No. 19367341, filed October 23, 2025, published April 23, 2026) covering intra-oral formulations of soft anticholinergic alkyl esters for treating excessive drooling associated with sialorrhea. The formulations are described as anhydrous and configured for intra-oral delivery of an effective amount of at least one soft anticholinergic ester to inhibit sialorrhea. CPC classifications include A61K 31/40 (heterocyclic compounds), A61P 1/02 (stomatological preparations), and C07D 207/10 and C07D 207/12 (pyrrole derivatives).
“Intra-oral formulations comprising soft anticholinergic alkyl esters are useful for treating excessive drooling conditions in subjects, such as humans, suffering from sialorrhea.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 211 changes logged to date.
What changed
Bodor Laboratories, Inc. filed USPTO patent application US20260108491A1 covering intra-oral formulations of soft anticholinergic alkyl esters designed to inhibit excessive drooling in subjects suffering from sialorrhea. The application (Application No. 19367341) was filed October 23, 2025 and published April 23, 2026, with Nicholas S. Bodor listed as inventor. The formulations are described as anhydrous intra-oral preparations providing an effective concentration of soft anticholinergic ester.
Parties monitoring pharmaceutical IP developments in sialorrhea therapeutics, anticholinergic drug delivery, or oral formulations should review this published application to assess freedom-to-operate considerations or potential licensing opportunities. The application does not itself grant enforceable patent rights; it establishes priority date for potential claims in the specified therapeutic and formulation categories.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS AND COMPOSITIONS FOR SOFT ANTICHOLINERGIC ESTERS
Application US20260108491A1 Kind: A1 Apr 23, 2026
Assignee
Bodor Laboratories, Inc.
Inventors
Nicholas S. BODOR
Abstract
Intra-oral formulations comprising soft anticholinergic alkyl esters are useful for treating excessive drooling conditions in subjects, such as humans, suffering from sialorrhea. Preferably, at least one soft anticholinergic ester is provided in an effective amount or concentration in an anhydrous intra-oral formulation that can inhibit excessive drooling resulting from a condition known as sialorrhea.
CPC Classifications
A61K 31/40 A61K 9/0056 A61K 9/006 A61K 9/2054 A61K 9/7007 A61K 47/38 A61K 47/40 A61P 1/02 C07D 207/10 C07D 207/12
Filing Date
2025-10-23
Application No.
19367341
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.